We are live on ! Find out more
SAGE

Sage Therapeutics
SAGE

Delisted

SAGE was delisted on the 30th of July, 2025.

Back to rankings

224 hedge funds and large institutions have $2.54B invested in Sage Therapeutics in 2023 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 72 increasing their positions, 76 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 18

30% more call options, than puts

Call options by funds: $21.6M | Put options by funds: $16.6M

14% more capital invested

Capital invested by funds: $2.22B → $2.54B (+$321M)

6% more funds holding

Funds holding: 212 → 224 (+12)

1.99% more ownership

Funds ownership: 88.53% → 90.53% (+2%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5% less repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 76

Holders
224
Holders Change
+12
Holders Change %
+5.66%
% of All Funds
3.52%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
31
Increased
72
Reduced
76
Closed
18
Calls
$21.6M
Puts
$16.6M
Net Calls
+$4.98M
Net Calls Change
-$3.09M

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$84.9M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$32.3M
3
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$31.7M
4
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$29.5M
5
JP Morgan Chase
JP Morgan Chase
New York
+$15.8M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$41.2M
2
Marshall Wace
Marshall Wace
United Kingdom
-$30.5M
3
BlackRock
BlackRock
New York
-$25.2M
4
State Street
State Street
Massachusetts
-$21.7M
5
Goldman Sachs
Goldman Sachs
New York
-$21.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
BPC
226
Banque Pictet & Cie
Switzerland
– -$849K -20,223 Closed
WG
227
Winton Group
United Kingdom
– -$812K -19,356 Closed
IC
228
Ikarian Capital
Texas
– -$747K -17,805 Closed
AC
229
AXQ Capital
New Jersey
– -$605K -14,412 Closed
AG
230
Algert Global
California
– -$599K -14,280 Closed
MG
231
Marex Group
– -$454K -10,814 Closed
GCP
232
GSA Capital Partners
United Kingdom
– -$450K -10,721 Closed
SC
233
Shay Capital
New York
– -$252K -6,000 Closed
QT
234
Quantamental Technologies
New York
– -$237K -5,653 Closed
CIC
235
Cornercap Investment Counsel
Georgia
– -$209K -4,984 Closed
TWA
236
TCI Wealth Advisors
Arizona
– -$13.4K -320 Closed
C
237
Covestor
United Kingdom
– -$13.9K -280 -98%
CA
238
Crewe Advisors
Utah
– -$2.31K -55 Closed
SC
239
Schubert & Co
Texas
– -$1.3K -31 Closed
Northwestern Mutual Wealth Management
240
Northwestern Mutual Wealth Management
Wisconsin
– -$420 -10 Closed
VFA
241
Values First Advisors
Tennessee
– -$40 -1 Closed
6 7 8 9
10

SAGE Hedge Fund Activity: Q2 2023 in Review

224 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Sage Therapeutics (SAGE) for Q2 2023, worth a combined $2.54B — up 14% from $2.22B a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new SAGE positions and 18 closed out — a net gain of 13 holders — while 72 added to existing stakes and 76 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $84.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $41.2M.

  • 224 institutional investors held Sage Therapeutics (SAGE) as of Q2 2023, up from 212 in Q1 2023.
  • Funds reported $2.54B of Sage Therapeutics stock for Q2 2023, up 14% quarter-over-quarter.
  • 31 funds opened new Sage Therapeutics positions in Q2 2023 and 18 closed out, a net change of +13 holders.
  • The largest Sage Therapeutics buyer in Q2 2023 was Fidelity Investments, an estimated $84.9M added.
  • The largest Sage Therapeutics seller in Q2 2023 was T. Rowe Price Associates, an estimated $41.2M sold.

Based on aggregated 13F filings for Q2 2023.